

Procalcitonin (PCT)

Diagnosis, monitoring and treatment surveillance of sepsis

CLIA



Human

Diagnostics Worldwide

Procalcitonin (PCT)

An important biomarker for bacterial infection – diagnosis, monitoring and treatment surveillance of sepsis

What is PCT?

Healthy people produce procalcitonin (PCT) in the cells of the thyroid gland. PCT is a precursor hormone of calcitonin and is not detectable in healthy individuals, because the synthesis of procalcitonin outside the thyroid gland is normally suppressed.

Why testing for PCT?

Bacterial versus viral Infections

Already in 1993, it was demonstrated that there is a positive correlation between high serum levels of PCT and patients with positive findings for bacterial infection and sepsis. Nevertheless, owing to its greater availability, C-reactive protein (CRP) has been widely used as a biomarker of infection and sepsis. However, PCT is often reported to be more superior to CRP, being more specific for sepsis and bacterial infection.



This is, because PCT starts to rise earlier and returns to normal concentration more rapidly than CRP, thereby allowing for an earlier diagnosis and better monitoring of disease progression (see figure 1).

In addition, PCT levels remain low in viral infections compared with bacterial infections. This makes PCT the most ideal biomarker for distinguishing bacterial infection from other non-infectious causes of inflammation.^{1, 2, 3, 6}




Fig. 1: PCT concentration increase faster after bacterial endotoxin exposure, compared to CRP levels (adapted from Meisner M.⁵)

However, bacterial infections may cause an inflammatory event, after e.g. a cut injury, an insect bite, burn or pneumonia. In some cases, the body is no longer able to fight the pathogens on its own, as a result blood poisoning (sepsis) occurs. One of the stimuli for the release of procalcitonin are bacterial endotoxins, e.g. lipopolysaccharides. Almost all organs can produce procalcitonin, which leads to a rapid increase of the PCT concentration in the blood, of up to 1,000 ng/ml within six to twelve hours. Clinically, it may be difficult to differentiate viral from bacterial infections. But the differentiation of the cause of an infection is crucial, because untreated bacterial infections may cause serious complications. In addition, treating viral illnesses or noninfective causes of inflammation with antibiotics is not only ineffective, but also contributes to the development of antibiotic resistance, increases costs, and adds the risks of toxicity and allergic reactions.⁶

Furthermore, PCT values reflect the severity of systemic sepsis, ranging from slightly elevated levels in minor infections to very high levels in severe sepsis or septic shock. Once the infection is under control, the procalcitonin concentration decreases again very quickly.

« In short, the higher the concentration of PCT, the more likely it is that the patient is experiencing a systemic infection or sepsis.» (see figure 2)

≥ 10 ng/ml	Septic shock	> Extremely high levels are found almost exclusively as a result of severe bacterial sepsis or septic shock, with a high mortality risk as a result of multiple organ failure
2 - < 10 ng/ml	Severe sepsis	> Indication of a severe systemic inflammation, probably due to infection or sepsis
0.5 - < 2 ng/ml	Sepsis likely	> Indication of a moderate systemic inflammation other conditions may also induce significant PCT rise e.g. trauma, surgery
0.05 - 0.5 ng/ml	Sepsis unlikely	> But inflammatory response is not excluded; possible localized infection
< 0.05 ng/ml	Healthy adult	

Fig. 2: PCT levels in the blood rise with increasing severity of infection (adapted from Meisner M.⁷).


Supporting antibiotic stewardship

In addition, more recently, it was shown that PCT can be used as a persuasive, evidence-based approach to a more rational use of antibiotics. This is because PCT mirrors the likelihood of bacterial infection and the severity of infection. Thus, PCT can provide guidance to antibiotic therapy, because serum levels of PCT decrease following administration of appropriate antibiotic therapies. In addition, a PCT-guided reduced use of antibiotics results in lower side-effects and an improvement in clinical outcomes.^{8,9}

« PCT determination is also used to help with the decision to initiate antibiotic therapy or to assess therapy response, thereby reducing the use of antibiotics. »^{10, 11}

Time matters – early PCT detection can help save lives

It is important to detect sepsis in a timely manner, because severe sepsis leads to a breakdown of the entire immune system. In a toxic septic shock, several organs fail simultaneously (multi-organ failure) and blood pressure drops massively. If sepsis has progressed to this stage the in-hospital mortality rates approaching 30–50%.¹² Timely drug and/or surgical treatment is therefore important for successful treatment.



Procalcitonin (PCT)

Diagnosis, monitoring and treatment surveillance of sepsis

Summary of Indications

- Aid in the diagnosis of sepsis
- Aid in the diagnosis of severe bacterial infections
- Monitoring of the response of antibiotic treatment



Product and order information



HumaCLIA 150

REF 15910

Random-access chemiluminescence immunoassay system

PCT HumaCLIA SR

REF 85020

Content

2 x 50 tests incl. calibrators

Measurement range

0.03-100 ng/ml

Reference interval

< 0.05 ng/ml

Sample volume

28 µl

PCT HumaCLIA SR Control

REF 85820

Content

2 levels each with 2 x 2 ml

References

1. Cleland D. A. et al. Procalcitonin. [Updated 2020 Sep 3]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK539794> (Status: 22 March 2021)
2. Assicot M. et al. High serum procalcitonin concentrations in patients with sepsis and infection. *Lancet*. 1999 Feb 27;341(8844):515-8. [PMC free article: PMC7141580] [PubMed: 8094770]
3. Samsudin I, Vasikaran SD. Clinical Utility and Measurement of Procalcitonin. *Clin Biochem Rev*. 2017 Apr;38(2):59-68. PMID: 29332972; PMCID: PMC5759088.
4. Philippe Linscheid et al. In Vitro and in Vivo Calcitonin I Gene Expression in Parenchymal Cells: A Novel Product of Human Adipose Tissue. *Endocrinology*. Volume 144, Issue 12, 1 December 2003, Pages 5578-5584, <https://doi.org/10.1210/en.2003-0854>
5. Meisner M. Procalcitonin: Experience with a new diagnostic tool for bacterial infection and systemic inflammation. *J Lab Med* 1999;23:263-72.
6. Simon L. et al. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. *Clin Infect Dis*. 2004 Jul 15;39(2):206-17. doi: 10.1086/421997. Epub 2004 Jul 2. Erratum in: *Clin Infect Dis*. 2005 May 1;40(9):1386-8. PMID: 15307030.
7. Meisner M. Procalcitonin - Biochemistry and Clinical Diagnosis. 1st ed. Bremen: UNI-MED; 2010. ISBN 978-3-8374-1241-3.
8. Schuetz P, Albrich W, Mueller B. Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future. *BMC Med*. 2011 Sep 22;9:107. [PMC free article: PMC3186747] [PubMed: 21936959]
9. Schuetz P. et al. Clinical Chemistry and Laboratory Medicine (CCLM). Band 57, Heft 9, Seiten 1308-1318. eISSN 1437-4331, ISSN 1434-6621, DOI: <https://doi.org/10.1515/cclm-2018-1181>.
10. Bouadma L. et al. Use of Procalcitonin to Reduce Patients' Exposure to Antibiotics in Intensive Care Units (PRORATA Trial): A Multicentre Randomised Controlled Trial. *Lancet*. 2010;375(9713):463-474. doi: 10.1016/S0140-6736(09)61879-1. Epub 2010 Jan 25. PMID: 20097417
11. Rhee C. Using Procalcitonin to Guide Antibiotic Therapy. *Open Forum Infect Dis*. 2016;4(1):ofw249. Published 2016 Dec 7. doi:10.1093/ofid/ofw249
12. Hotchkiss RS et al. Sepsis and septic shock. *Nat Rev Dis Primers*. 2016;2:16045. Published 2016 Jun 30. doi:10.1038/nrdp.2016.45

Your local distribution partner